[Etofibrate and clofibrate in double blind study].
作者信息
Rahlfs V W, Zimmermann H, Safer A
出版信息
Dtsch Med Wochenschr. 1976 Jul 30;101(31):1168-9.
PMID:789039
Abstract
摘要
相似文献
1
[Etofibrate and clofibrate in double blind study].双盲研究中的益多酯和氯贝丁酯
Dtsch Med Wochenschr. 1976 Jul 30;101(31):1168-9.
2
[Etofibrate and clofibrate in a double-blind trial on patients with raised serum-lipid levels (author's transl)].益多酯与氯贝丁酯对血清脂质水平升高患者的双盲试验（作者译）
Dtsch Med Wochenschr. 1975 Nov 28;100(48):2486-8. doi: 10.1055/s-0028-1106571.
3
[Study of the antilipemic effect of etofibrate (Lipo-Merz)].[益多酯（利波立美）的降血脂作用研究]
Pol Tyg Lek. 1983 Apr 25;38(17):529-32.
4
The chemotherapy of hypercholesterolaemia.
Acta Cardiol. 1969;24(1):47-55.
5
[Treatment of hyperlipoproteinemias (author's transl)].
G Ital Cardiol. 1974;4(3):332-40.
6
Colestipol and clofibrate in hypercholesterolemia.考来替泊与氯贝丁酯治疗高胆固醇血症
Clin Pharmacol Ther. 1974 Aug;16(2):291-6. doi: 10.1002/cpt1974162291.
7
Controlled clinical trial of a new bile acid-sequestering resin, colestipol, in the treatment of hypercholesterolaemia.一种新型胆汁酸螯合剂考来烯胺治疗高胆固醇血症的对照临床试验。
Med J Aust. 1973 Jun 23;1(25):1223-7.
8
[Clinical and therapeutic evaluation of simfibrate compared toclofibrate in atherosclerotic patients].
Clin Ter. 1979 Feb 15;88(3):267-79.
9
[Real or alleged risks of clofibrate derivatives and certain risks of their prohibition].[氯贝丁酯衍生物的实际或声称风险及其被禁止的某些风险]
Nouv Presse Med. 1979 Mar 31;8(15):1223-5.
10
[The effect of a lipid-reducing clofibrate-inositolnicotinate combination compared to clofibrate. A double-blind study].
Med Welt. 1975 Apr 4;26(14):655-63.
Zotero 插件